Objective: To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC).
Material And Methods: We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non-clear cell RCCs were analyzed.
Results: We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23-88) years. Median tumor size was 3 (1-11)cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively.
Conclusion: Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084474 | PMC |
| http://dx.doi.org/10.1016/j.urolonc.2016.08.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immature PIT1-lineage Pituitary Neuroendocrine Tumors/Adenomas, a Morphologically Unique Pituitary Neuroendocrine Tumors/Adenomas Commonly With Cytologic Atypia Features and a Predilection for Aggressive Clinical Potential.
Am J Surg Pathol
December 2024
Departments of Pathology.
Immature PIT1-lineage pituitary neuroendocrine tumors (PitNETs)/adenomas (Immature PIT1-lineage tumors) are a rare and underrecognized subtype of PitNETs that exhibits distinct cytologic atypia features and aggressive clinical potential. This study characterizes the clinical, radiological, histologic, and immunohistochemical features of 15 immature PIT1-lineage tumors identified from 1084 PitNETs patients over 5 years. Our cohort of 6 males and 9 females had a median age of 37.
View Article and Find Full Text PDFComprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.
Heliyon
November 2024
Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, 710061, China.
Article Synopsis
- CD73 is an important molecule involved in immune regulation and its role in the tumor microenvironment was investigated using multiple cancer databases, revealing elevated levels in several cancer types like esophageal carcinoma and glioblastoma.
- The study found that high CD73 expression was often linked to poor overall survival in various cancers such as breast and lung cancers, although in some cases (like kidney and uterine cancers), high expression was associated with better outcomes.
- Additionally, tumors with high CD73 expression showed increased immune scores and positive correlations with immune cell infiltration, indicating a complex relationship between CD73 and the immune response in tumors.
[Non-clear cell renal cell carcinoma].
Urologie
December 2024
Medizinische Klinik II, Universitätsklinik, J.W. Goethe Universität, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Deutschland.
Non-clear cell renal cell carcinomas (nccRCC) account for approximately 20-25% of renal cell carcinomas. Approximately 20 different histologically and/or molecularly defined entities are subsumed under nccRCC. Many entities only have a share of 1% or less.
View Article and Find Full Text PDFGATA3 Expression in Solid Vimentin-Negative Eosinophilic Renal Epithelial Tumors-A Comprehensive Study of 48 Tumors.
Int J Surg Pathol
November 2024
Department of Pathology, The University of Chicago, Chicago, IL, USA.
Vimentin-negative solid eosinophilic renal tumors, such as renal oncocytoma, chromophobe renal cell carcinoma (chromophobe RCC), low-grade oncocytic tumor (LOT) of the kidney, and eosinophilic vacuolated tumor (EVT), often present diagnostic challenge to pathologists as they can have significant morphologic overlap. Recent studies have shown that the LOT is consistently positive for GATA3. To test the utility of GATA3 in this potentially challenging diagnostic setting, we investigated GATA3 expression in 48 vimentin-negative solid eosinophilic renal tumors with unequivocal diagnosis, which included 19 LOTs, 3 EVTs, 12 chromophobe RCCs, 11 renal oncocytomas (ROs), and 3 -mutated renal tumors.
View Article and Find Full Text PDFImpact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Urol Oncol
November 2024
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
Modern advances in systemic and localized therapies for patients with renal cell carcinoma (RCC) have significantly improved patients' outcomes. If disease progression occurs after initial treatment, clinicians often have multiple options for a first salvage therapy. Because salvage and initial treatments both may affect overall survival time, and they may interact in unanticipated ways, there is a growing need to determine sequences of initial therapy and first salvage therapy that maximize overall survival while maintaining quality of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!